Jefferies Financial Group Inc JEF

$45.97 +0.72 (1.59%)

Valuation

Market cap
8,766,871,000
Revenue TTM
$7,343,750,000
Net income TTM
$710,480,000
PE ratio
11.52
Forward PE
11.18
Profit margin
9.67%
Debt to equity
1.99

Trading

Volume
2,087,500
Avg volume
2,131,808
Day's range
$45.49 – $46.57
Shares out
193,743,000
Stochastic %K
45%
Beta
1.57
Analysts
Sell
Price target
$56.42

Price

Company profile

Jefferies Financial Group Inc. operates as an investment banking and capital markets firm in the Americas, Europe, the Middle East, and the Asia-Pacific. It operates in two segments, Investment Banking and Capital Markets, and Asset Management. The company provides investment banking and advisory services for mergers or acquisitions, debt financing, restructurings, and private capital advisory transactions; underwrit...

Show more

Jefferies Financial Group Inc. operates as an investment banking and capital markets firm in the Americas, Europe, the Middle East, and the Asia-Pacific. It operates in two segments, Investment Banking and Capital Markets, and Asset Management. The company provides investment banking and advisory services for mergers or acquisitions, debt financing, restructurings, and private capital advisory transactions; underwriting and placement services related to corporate debt, municipal debt, mortgage-backed and asset-backed securities, equity and equity-linked securities, and loan syndication services; and corporate lending services. It also offers financing, securities lending, and other prime brokerage services; equities research, sales, and trading services; wealth management services; and online foreign exchange trading services. In addition, the company provides investment-grade distressed debt securities, U.S. and European government and agency securities, municipal bonds, leveraged loans, emerging markets debt, interest rates, and credit index derivative products; and manages and offers services to a diverse group of alternative asset management platforms across a spectrum of investment strategies and asset classes. It serves public companies, private companies, sponsors and owners, institutional investors, and government entities. The company was formerly known as Leucadia National Corporation and changed its name to Jefferies Financial Group Inc. in May 2018. Jefferies Financial Group Inc. was founded in 1962 and is headquartered in New York, New York.

Industry
Capital Markets
Sector
Financial Services
Phone
212 284 2300
Website
https://www.jefferies.com
Address
520 Madison Avenue, 10th Floor, New York, United States

Latest news

Stocktwits

topstockalerts Oct 2, 9:13 PM
Jefferies’ monthly construction weather monitor showed that September weather patterns across the Northern Hemisphere largely extended Q3 trends. Europe was generally drier than usual, with France, Germany, Spain and Italy recording fewer extreme-rainfall days than last year, while Poland and Finland saw heavier rainfall. Wildfires in Spain and France and July-August heat waves caused disruptions, while Romania and most Nordic countries remained unusually dry. In the U.S., Q3 rainfall was slightly below last year’s levels, although conditions varied regionally. Areas along the northern Mississippi saw wetter weather, while the South was moderately drier. New York, Pennsylvania and Connecticut experienced above-normal rainfall, while Texas recorded fewer rainy days after an especially wet Q2. The U.S. hail season also lasted longer than usual, with cumulative hailstorms 4% above last year through September, following a weaker season in 2025. $JEF
0 replies
topstockalerts Oct 1, 1:32 AM
Jefferies initiated coverage of Molbio Diagnostics with a Buy rating and an INR 1,600 price target, naming it a high-conviction pick in India’s medical supplies and devices sector. The broker highlighted Molbio’s differentiated point-of-care molecular diagnostics platform and expects 22% revenue CAGR and 47% profit-after-tax CAGR for FY26-29E, driven by product expansion and operating leverage. Molbio’s flagship Truenat platform accounted for 86% of FY26 sales and operates in an oligopolistic market. Developed after 13 years of R&D, the portable, battery-powered molecular diagnostics system can test for 30 diseases and is patented in more than 100 countries. Jefferies sees significant growth potential versus larger platforms such as GeneXpert, with Truenat generating about $130 million in revenue versus roughly $3 billion for GeneXpert. Beyond molecular diagnostics, Molbio has expanded into portable X-ray through Prorad and digital pathology via Optrascan. $JEF
0 replies
KryptonResearch14 Sep 30, 12:01 AM
$JEF The post-print on the Jefferies pre-mortem: fiscal Q3 landed Monday after the close, and the fee-capture read was right. Investment banking did 1.33 billion, up 17% and a record. Equities hit a record too at 626 million, up 29%. The totals: revenue 2.22 billion, up 8.5%, a touch above the 2.21 billion estimate. GAAP EPS 1.08 vs 1.04 expected. The stock still fell about 4% after hours. The drag is visible in the mix: Zacks shows asset-management net revenue of 85.64 million vs 113.92 million estimated, down about 52% from last year. Two things to watch. First, consensus EPS had been revised up 8.1% in the month before the print, so the beat was partly priced. Second, this is the first read on 2026 deal revenue ahead of the bulge brackets in mid-October, and the record is at the middle-market end of the fee pool. Tracking this into Goldman and Morgan Stanley.
0 replies
briefingcom Sep 29, 3:37 PM
$JEF: Jeffries delivered a Q3 beat as dealmaking and trading momentum drove record Investment Banking, Advisory, and Equities revenue. But higher expenses, weaker Fixed Income, and a sharp drop in Asset Management revenue limited the flow-through to profitability. https://www.briefing.com/story-stocks/archive/2026/9/29/jefferies-dealmaking-engine-accelerates-in-q3-as-asset-management-loses-ground-(jef)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link #Earnings #MergersAndAcquisitions #investmentbanking #financial
0 replies
alby777 Sep 29, 12:28 PM
$JEF https://www.reuters.com/business/finance/japans-smbc-raises-stake-jefferies-about-20-2025-09-19/
0 replies
Estimize Sep 29, 10:03 AM
$JEF reported 1.08 EPS and 2,222 revenue for Q3. http://www.estimize.com/intro/jef?chart=historical&metric_name=eps&utm_content=JEF&utm_med
0 replies
DonCorleone77 Sep 29, 2:01 AM
$NBIX $GEN $RTX $MTN $JEF AFTER-HOURS MOVERS: Currently Higher After Earnings: - Sangoma Technologies (SANG) up 42.1% - IDT Corporation (IDT) up 2.6% Currently Also Higher: - Summit Therapeutics (SMMT) up 17.8% after AstraZeneca (AZN) - Navitas Semiconductor (NVTS) up 12.4% after being awarded ALATTIS program by U.S. Armyinvestment of $2.0B - AAR Corp. (AIR) up 4.3% after agreement to acquire 65% interest in MRO Holdings for $1.8B and Q1 pre-announcement - Neurocrine Biosciences (NBIX) up 0.9% after naming new Chief Medical Officer. - Gen Digital (GEN) up 1.6% after positive Q2 pre-announcement - RTX Corporation (RTX) up 0.9% after being awarded $20.7B U.S. Air Force multi-year contract Currently Lower After Earnings: - Vail Resorts (MTN) down 1.1% - Jefferies Financial (JEF) down 0.8% - ReposiTrak (TRAK) down 2.3%
0 replies
topstockalerts Sep 29, 1:02 AM
Jefferies Financial Group reported mixed fiscal Q3 2026 results after the close. Adjusted EPS of $1.08 beat the $1.00 consensus, while total net revenues of $2.22 billion slightly exceeded the $2.20 billion estimate. However, the stock came under pressure as investors focused on weaker segment performance. Fixed Income and Asset Management were the main drags. Asset management fees and investment returns fell to just $34 million, hurt by weak performance across several fund strategies, including the ongoing liquidation of Point Bonita, and lower fees from internally managed funds. Fixed Income also remained challenged. These declines offset record quarterly net revenues in Investment Banking and Equities, with investment banking revenue up 17% to $1.33 billion and equity underwriting surging 69%. The board declared a $0.40 quarterly dividend and renewed a $250 million share-repurchase authorization. $JEF
0 replies